Zoetis (ZTS) | Stock Overview & Key Data
Zoetis Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $249.27 on December 27, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
United Therapeutics
UTHR
|
25.11B Large-cap | 0.90% | -3.34% | 2.86% | 9.85% | 10.64% | 92.68% | 137.11% | 205.88% | 434.68% | 903.79% | 2,026.01% |
|
Viatris
VTRS
|
16.99B Large-cap | 2.45% | -0.97% | 20.80% | 39.97% | 30.98% | 84.75% | 60.16% | 15.57% | -63.39% | -26.00% | -21.07% |
| 14.00B Large-cap | -20.10% | -40.20% | -24.65% | -0.98% | -16.80% | 20.24% | 2,888.89% | 6,625.00% | 6,625.00% | 6,625.00% | 6,625.00% | |
|
Intra-Cellular
ITCI
|
14.05B Large-cap | N/A | N/A | N/A | N/A | N/A | 92.68% | 104.13% | 700.67% | 449.92% | 632.61% | 632.61% |
Ownership & Short Interest
Calculate Your Zoetis Investment Returns
Long-Term Investment Performance Analysis
Zoetis stock price in Jul 2016 was $50.26, A $1,000.00 lump sum investment in Zoetis made 8 years ago would be worth approximately $3,324.71 today, representing a outstanding return of 232.47%. This translates to an annualized return (CAGR) of 14.41%.
8 Years 11 Months Investment Scenario (Jul 2016 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ZTS's 52-week high and low?
- In the last 52 weeks, Zoetis reached a high of $200.33 (on September 19, 2024) and a low of $139.70 (on April 9, 2025).
- What is the market cap and P/E ratio for ZTS?
- Curious about Zoetis's size and valuation? Its market capitalization stands at 49.75B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.58, and the forward P/E (looking ahead) is 15.61.
- Does ZTS pay dividends? If so, what's the yield?
- Yes, Zoetis is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.21%, and the company has paid an average of $1.80 per share annually over the past 3 years.
- Who are Zoetis's main competitors or similar companies to consider before investing?
When looking at Zoetis, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% United Therapeutics
UTHR25.11B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 137.11% Viatris
VTRS16.99B Healthcare Drug Manufacturers - Specialty & Generic 84.75% 60.16% Regencell Bioscience
RGC14.00B Healthcare Drug Manufacturers - Specialty & Generic 20.24% 2,888.89% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Zoetis Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Zoetis's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 65.99%, the Debt to Equity ratio from the most recent quarter is 279.59, and its Gross Profit Margin stands at 70.17%.
- What is the recent revenue and earnings growth for ZTS?
- Looking at Zoetis's growth, its revenue over the trailing twelve months (TTM) was $9B. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.00%, and quarterly earnings saw a YoY growth of 3.80%.
- How much of ZTS stock is held by insiders and institutions?
- Wondering who owns Zoetis stock? Company insiders (like executives and directors) hold about 0.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.50%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.